About ponatinib
Tyrosine kinase inhibitor
Used for
- Certain types of chronic myeloid leukaemia (CML)
- Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL)
Usual adult dose
Usually 45 mg once daily; doctors may reduce the dose based on response or side effects.
Common side effects
- High blood pressure
- Rash or dry skin
- Abdominal pain or constipation
- Low blood counts
Important warnings
- Can cause serious blood clots, heart attack, stroke, or circulation problems.
- May cause pancreatitis, liver injury, or severe bleeding.
- Can harm an unborn baby; effective contraception is needed during treatment.
- Regular blood tests and blood-pressure monitoring are required.
Pregnancy
Can cause fetal harm. Avoid during pregnancy; use effective contraception during treatment and for three weeks after the final dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the final dose.
Interactions
- Strong CYP3A inhibitors can raise ponatinib levels.
- Strong CYP3A inducers can lower ponatinib levels.
- Acid-reducing medicines may affect absorption; check with a clinician or pharmacist.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.